Trial Profile

Phase II Study of Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (The DUREC Trial)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
Indications Adenocarcinoma; Rectal cancer
Focus Therapeutic Use
Acronyms DUREC

Most Recent Events

24 Oct 2023 Results (n=61) assessing efficacy and safety of TNT in combination with the anti-PD-L1 durvalumab presented at the 48th European Society for Medical Oncology Congress
31 May 2020 Trial design results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
17 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com